Acrivon Therapeutics (ACRV) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 9.4% versus a loss of 14.1%. Acrivon Therapeutics is the larger company by market cap ($70.3 million vs $67.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | MAIA |
|---|---|---|
| Share price | $1.64 | $1.10 |
| Market cap | $70.28M | $67.92M |
| 1-day change | -6.82% | -1.79% |
| YTD return | -31.95% | -28.10% |
| 1-year return | -9.39% | -14.06% |
| Forward P/E | — | 0.99 |
| EPS (TTM) | $-1.88 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-77.91M | $-22.40M |
| 52-week high | $3.56 | $3.19 |
| 52-week low | $1.27 | $0.87 |
| Distance from 52-week high | -53.93% | -65.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +601.22% | +990.91% |
| Average volume | 318.58K | 481.94K |
| Shares outstanding | 42.85M | 61.74M |
| Employees | 74 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ACRV vs MAIA FAQ
Which is bigger, Acrivon Therapeutics or MAIA Biotechnology?
Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $70.28M compared with $67.92M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, ACRV or MAIA?
ACRV returned -9.39% over the past 12 months, compared with -14.06% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.